NVG-2089

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

This is an open-label study. This means that you and the study doctor will know what dose of the study drug (NVG-2089) you are receiving.

Eligible patients will be:

- Adults aged 18 years or older
- Diagnosed with active CIDP
- Either:
    - Willing to discontinue current treatment of intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) OR
    - Newly diagnosed with CIDP and have never been treated

You will be in the study for up to 26 weeks (about 6 ½ months) and you will visit the study site approximately 11 times and have 1 visit by phone call. Travel assistance will be provided for participants who qualify for the trial.

Our current US sites are in California, Connecticut, Florida, Kentucky and Texas.

For more information on this Phase 2 study, please contact bella.oguno@nuvigtx.com